Search

Displaying results 821 - 830 of 2430 in total
  1. Drug

    Sotorasib

    go.drugbank.com/drugs/DB15569
    ApprovedInvestigational

    Sotorasib, also known as AMG-510, is an acrylamide-derived KRAS inhibitor developed by Amgen. It is indicated in the treatment of adult patients with KRAS G12C mutant non-small cell lung cancer. This mutation makes up >50% of all KRAS...

    Categories: P-glycoprotein inhibitors, Cytochrome P-450 Substrates
  2. Drug

    Fennel

    go.drugbank.com/drugs/DB15615
    Approved

    Categories: Cytochrome P-450 CYP2D6 Inhibitors, Cytochrome P-450 CYP2E1 Inhibitors
  3. Drug

    Selpercatinib

    go.drugbank.com/drugs/DB15685
    ApprovedInvestigational

    Selpercatinib is a kinase inhibitor with enhanced specificity for RET tyrosine kinase receptors (RTKs) over other RTK classes. Enhanced RET (Rearranged during transfection) oncogene expression is a hallmark of many cancers. Although mult...

    Categories: P-glycoprotein inhibitors, P-glycoprotein substrates
  4. Drug

    Fenchone

    go.drugbank.com/drugs/DB15918
    Investigational

    Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP2A6 Substrates
  5. Drug

    Homochlorcyclizine

    go.drugbank.com/drugs/DB15979
    Investigational

    Categories: Cytochrome P-450 CYP2D6 Inhibitors, Cytochrome P-450 Enzyme Inhibitors
  6. Drug

    Garlic oil

    go.drugbank.com/drugs/DB15989
    Investigational

    Categories: Cytochrome P-450 CYP2C19 Inhibitors, Cytochrome P-450 CYP2C9 Inhibitors
  7. Drug

    Finerenone

    go.drugbank.com/drugs/DB16165
    ApprovedInvestigational

    Finerenone, or BAY 94-8862, is a mineralocorticoid receptor antagonist indicated to reduce the risk of sustained decline in glomerular filtration rate, end stage kidney disease, cardiovascular death, heart attacks, and hospitalization du...

    Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP1A1 Substrates
  8. Drug

    Paltusotine

    go.drugbank.com/drugs/DB16277
    ApprovedInvestigational

    Paltusotine is a selective somatostatin receptor agonist: It mimics the biological actions of endogenous somatostatin, which activates the somatostatin 2 receptor (SST2) to block the secretion of growth hormone (GH) and decreases the pro...

    Categories: P-glycoprotein inhibitors, P-glycoprotein substrates
  9. Drug

    Vicagrel

    go.drugbank.com/drugs/DB16349
    Investigational

    Vicagrel is under investigation in clinical trial NCT03599284 (The Efficacy, Safety and Pharmacokinetic of Antiplatelet Therapy for Vicagrel).

    Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP2C19 Substrates
  10. Drug

    Mobocertinib

    go.drugbank.com/drugs/DB16390
    ApprovedInvestigationalWithdrawn

    Mobocertinib is a kinase inhibitor targeted against human epidermal growth factor receptor (EGFR). It is used specifically in the treatment of non-small cell lung cancer (NSCLC) caused by exon 20 insertion mutations in the EGFR gene, whi...

    Categories: Cytochrome P-450 Substrates, P-glycoprotein inhibitors